Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 2;33(7):2997-3005.
doi: 10.1016/j.ymthe.2024.10.019. Epub 2024 Oct 28.

Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina

Fabio Dell'Aquila  1 , Roberto Di Cunto  2 , Elena Marrocco  3 , Eugenio Del Prete  3 , Alfonso D'Alessio  2 , Lucia De Stefano  3 , Simone Notaro  3 , Edoardo Nusco  3 , Alberto Auricchio  4
Affiliations

Combined intraocular and intravenous gene delivery for therapy of gyrate atrophy of the choroid and retina

Fabio Dell'Aquila et al. Mol Ther. .

Abstract

Gyrate atrophy of the choroid and retina (GACR) is due to ornithine aminotransferase (OAT) deficiency, which causes hyperornithinemia, leading to retinal pigment epithelium, followed by choroidal and retinal degeneration. Adeno-associated virus serotype 8 (AAV8) vector-mediated OAT (AAV8-OAT) liver gene transfer reduces ornithinemia in the Oat-/- mouse model of GACR and improves retinal function and structure. Since OAT is expressed in various tissues including the retina, we investigated the efficacy of restoration of OAT expression in either retina or liver or both tissues on the retinal phenotype of Oat-/- mice. Intravenous and subretinal administration of AAV8-OAT resulted in intraocular and liver OAT expression with reduced ornithinemia after intravenous AAV8-OAT administration, while intraocular ornithine levels were significantly reduced only following combined gene delivery. Accordingly, only Oat-/- animals treated with combined intravenous and subretinal AAV8-OAT administrations showed significant improvements in both retinal morphology and function. This work shows the benefits of combined liver and retinal OAT supplementation for the treatment of GACR.

Keywords: AAV; GACR; combined administration; eye; gene therapy; gyrate atrophy of the choroid and retina; intravenous; liver; ornithine amino transferase; subretinal.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests A.A. and F.D.A. are co-inventors of the patent entitled “GENE THERAPY FOR GYRATE ATROPHY OF THE CHOROID AND RETINA” (international no. WO/2023/213817), which protects the combined gene therapy approach for GACR.

References

    1. Takki K.K., Milton R.C. The Natural History of Gyrate Atrophy of the Choroid and Retina. Ophthalmology. 1981;88:292–301. doi: 10.1016/S0161-6420(81)35031-3. - DOI - PubMed
    1. Peltola K.E., Näntö-Salonen K., Heinonen O.J., Jääskeläinen S., Heinänen K., Simell O., Nikoskelainen E. Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. Ophthalmology. 2001;108:721–729. doi: 10.1016/S0161-6420(00)00587-X. - DOI - PubMed
    1. Ratzlaff K., Baich A. Comparison of ornithine aminotransferase activities in the pigment epithelium and retina of vertebrates. Comp. Biochem. Physiol. B. 1987;88:35–37. doi: 10.1016/0305-0491(87)90075-7. - DOI - PubMed
    1. Bernstein S.L., Wong P. Regional expression of disease-related genes in human and monkey retina. Mol. Vis. 1998;4:24. doi: 10.7939/R3N29P68P. - DOI - PubMed
    1. Kim H.R., Rho H.W., Park J.W., Park B.H., Kim J.S., Lee M.W. Assay of Ornithine Aminotransferase with Ninhydrin. Anal. Biochem. 1994;223:205–207. doi: 10.1006/abio.1994.1574. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources